Related Experiment Video

Updated: Jun 7, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

Gemcitabine causes minimal modulation of carboplatin-DNA monoadduct formation and repair in bladder cancer cells

Sisi Wang1, Hongyong Zhang, Michael Malfatti

  • 1Division of Hematology & Oncology, Department of Internal Medicine, UC Davis Cancer Center, Sacramento, California 95817, USA.

Chemical Research in Toxicology
|October 30, 2010
PubMed

Insights

This study shows that measuring carboplatin-DNA adducts using microdoses is a viable method for assessing cellular resistance, even when combined with gemcitabine chemotherapy.

Area of Science:

  • Oncology
  • Pharmacology
  • Biochemistry

Background:

  • Carboplatin is a widely used chemotherapy drug.
  • Assessing cellular resistance to carboplatin is crucial for effective cancer treatment.
  • Combination chemotherapy regimens are common but can alter drug efficacy.

Purpose of the Study:

  • To develop and validate a method for identifying cellular resistance to carboplatin.
  • To determine if microdosing of carboplatin can be used to measure DNA adducts.
  • To investigate the impact of gemcitabine on carboplatin-DNA adduct formation.

Main Methods:

  • Utilizing accelerator mass spectrometry (AMS) to quantify carboplatin-DNA adducts.
  • Employing microdoses of carboplatin (approximately 1/100th of the therapeutic dose).
  • Exposing cells to carboplatin alone and in combination with gemcitabine at various doses and schedules.

Main Results:

  • Carboplatin-DNA adducts were successfully measured using AMS and microdoses.
  • The addition of gemcitabine did not substantially alter carboplatin-DNA adduct levels.
  • No significant differences in adduct levels were observed across different combination doses and schedules.

Conclusions:

  • Microdosing with AMS is a feasible approach for characterizing carboplatin resistance.
  • This method remains valid even when carboplatin is administered in combination with gemcitabine.
  • The findings support the use of microdosing for personalized carboplatin resistance assessment in combination therapy.

More Related Videos

An Orthotopic Bladder Cancer Model for Gene Delivery Studies07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...